Skip to main content
SpringerLink
Log in

The anticancer drug, cisplatin, increases the naturally occurring cell-mediated lysis of tumor cells

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

It has been proposed that a component of the antitumor potential of the chemotherapeutic agent, cisplatin, resides in the host's ability to respond to cisplatintreated tumor cells. Here we report that tumor cells that are normally resistant to lysis mediated by naturally occurring cytotoxic cells showed an increased sensitivity to lysis mediated by murine spleen cells or human peripheral blood monocytes and lymphocytes when cisplatin was added at the beginning of the lytic assay. This was shown for the lysis of both murine and human tumor cells. The pretreatment of tumor cells, but not effector cells with cisplatin caused an increase in lysis in the presence of murine spleen cells or human peripheral blood leukocytes, indicating that the effect of cisplatin is to reduce resistance to lysis by these effector cells. The lysis of tumor cells by naturally occurring cytotoxic cells was blocked by antibodies specific for tumor necrosis factor. In addition, the ability of cisplatin to increase lysis was seen with cells that are sensitive to natural cytotoxic cells, but not with cells that are sensitive to natural killer cells. These results suggest that the effector cells that mediate the lysis of these tumor cells in the presence of cisplatin are likely to be natural cytotoxic cells. The ability of cisplatin to increase the lysis of tumor cells by naturally occurring cytotoxic cells indicates that these cells may be a host defense mechanism that contributes to the anticancer potential of cisplatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alberts DS, Chen HSB (1980) Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: Cloning of human tumor cells. Alan Liss Inc, New York, p 3518

    Google Scholar 

  2. Bagasra O, Currao L, DeSouza LR, Oosterhuis JW, Damjanov (1985) Immune response of mice exposed to cis-diamminedichloroplatinum. Cancer Immunol Immunother 19:142

    Google Scholar 

  3. Chary KK, Higby DJ, Henderson ES, Swinerton KD (1977) Phase I study of high dose cis-dichlorodiammineplatinum (II) with forced diuresis. Cancer Treat Rep 61:367

    Google Scholar 

  4. Collins JL, Patek PQ, Cohn M (1981) Tumorigenicity and lysis by natural killers. J Exp Med 153:89

    Google Scholar 

  5. Collins JL, Patek PQ, Cohn M (1982) In vivo surveillance of tumorigenic cells transformed in vitro. Nature 299:169

    Google Scholar 

  6. Collins JL, Patek PQ, Lin Y, Cohn M (1983) The cloned cell line L10A2. J expresses natural cytotoxic activity. Cell Immunol 103:191

    Google Scholar 

  7. Collins JL, Lin Y, Patek PQ (1986) Dissociation of contactnoninhibition in vitro and tumorigenicity in vivo. Cell Biol Int Rep 10:789

    Google Scholar 

  8. Collins JL, Kao M-S, Patek PQ (1987) Humans express natural cytotoxic (NC) cell activity that is similar to murine NC cell activity. J Immunol 138:4180

    Google Scholar 

  9. Epstein R, Cohn M (1978) T-cell inhibition of humoral responsiveness. I. Experimental evidence for restriction by K- and/or D-end of the H-2 complex. Cell Immunol 39:110

    Google Scholar 

  10. Gottlieb JA, Drewink OB (1975) Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep 59:621

    Google Scholar 

  11. Higby DJ, Wallace HJ, Albert DJ, Holland JF (1974) Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer 33:1219

    Google Scholar 

  12. Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, King JJ (1975) Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep 59:647

  13. Kiessling R, Klein E, Wigzell H (1975) ‘Natural’ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Clin Immunol 5:112

    Google Scholar 

  14. Kleinerman ES, Zwelling LA (1984) Effects of cisplatin, bleomycin and DTIC on immune function in vitro and in vivo. Clin Immunol Allergy 4:279

    Google Scholar 

  15. Kociba RJ, Sleight SD, Rosenberg B (1970) Inhibition of Dunning ascitic leukemia and Walker 256 carcinosarcoma with cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother Rep 54:325

    Google Scholar 

  16. Lin Y, Collins JL, Patek PQ, Cohn M (1983) An analysis of the sensitivity of somatic cell hybrids to natural killer and natural cytotoxic cell-mediated lysis. J Immunol 131:1154

    Google Scholar 

  17. Lozzio CB, Lozzio BB (1975) Human myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 45:321

    Google Scholar 

  18. Patek PQ, Collins JL, Cohn M (1978) Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis. Nature 276:510

    Google Scholar 

  19. Patek PQ, Collins JL, Cohn M (1983) Evidence that cytotoxic T-cells and natural cytotoxic cells use different lytic mechanisms to lyse the same targets. Eur J Immunol 13:433

    Google Scholar 

  20. Patek PQ, Lin Y, Collins JL, Cohn M (1986) In vivo or in vitro selection for resistance to natural cytotoxic cell lysis selects for variants with increased tumorigenicity. J Immunol 136:741

    Google Scholar 

  21. Patek PQ, Lin Y, Collins JL (1987) Natural cytotoxic cells and tumor necrosis factor activate similar lytic mechanisms. J Immunol 138:1641

    Google Scholar 

  22. Rosenberg B (1980) Enhanced antigenicity as a possible mode of action of platinum antitumor drugs. In: Advances in antimicrobial and antineoplastic chemotherapy, vol II. University Park Press, Baltimore, p 101

    Google Scholar 

  23. Rosenberg B (1980) Cisplatin: its history and possible mechanism of action. In: Cisplatin: current status and new developments. Academic Press, New York, p 9

    Google Scholar 

  24. Rosenberg B, VanCamp L (1970) The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res 30:1799

    Google Scholar 

  25. Rosenberg B, VanCamp L, Trosko J, Mansour VH (1969) Platinum compounds: a new class of potent antitumor agents. Nature 222:385

    Google Scholar 

  26. Schlaefli E, Ehrke MJ, Mihich E (1983) The effects of dichloro-trans-dihydroxy-bis-isopropylamine-platinum IV on the primary cell mediated cytotoxic response. Immunopharmacology 6:107

    Google Scholar 

  27. Scovell WM, O'Connor T (1977) Interaction of aquated cis-[(NH3)2PtII] with nucleic acid constituents. J Am Chem Soc 99:120

    Google Scholar 

  28. Stutman O, Cuttito MJ (1981) Normal levels of natural cytotoxic cells against solid tumors in NK deficient beige mice. Nature 290:254

    Google Scholar 

  29. Talley RW (1970) Chemotherapy of a mouse reticulum cell sarcoma with platinum salts. Proc Am Assoc Cancer Res 11:78

    Google Scholar 

  30. Timonen T, Ortaldo JR, Herberman RB (1981) Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med 153:569

    Google Scholar 

  31. Vonka V, Kutinova L, Drobnik J, Brauerova J (1972) Increase of Epstein-Bar-virus-positive cells in EB3 cultures after treatment with cis-dichlorodiammine-platinum (II). J Natl Cancer Inst 48:1277

    Google Scholar 

  32. Welsch CW (1971) Growth inhibition of rat mammary carcinoma induced by cis-platinum diamminodichloride II. J Natl Cancer Inst 47:1071

    Google Scholar 

  33. Wright KC, Carrasco CH, Wallace S, Stephens LC (1985) Treatment of the rabbit V-2 carcinoma with intralesional cisplatin. Chemother 31:60

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Oncology Division, Washington University School of Medicine, 4911 Barnes Hospital Plaza, 63110, St. Louis, MO, USA

    John Leslie Collins & Ming-Shian Kao

Authors
  1. John Leslie Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ming-Shian Kao
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Collins, J.L., Kao, MS. The anticancer drug, cisplatin, increases the naturally occurring cell-mediated lysis of tumor cells. Cancer Immunol Immunother 29, 17–22 (1989). https://doi.org/10.1007/BF00199911

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00199911

Keywords

Search

Navigation